Referencias

Referencias
l. Jacobson TA, Janes PH & Roth EM. Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia:
overview of efficacy and safety. Clinical Lipidology. 2010;5(5):627-649.
2. Machado-Duque ME, Gaviria-Mendoza A, Machado-Alba JE. Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia. J Prim Care Community Health. 2020 JanDec; ll:2150132720977733.
3. Mach F. Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid
modification to reduce cardiovascular risk. EurHeartJ.2020Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
4. Kim KJ, Kim SH, Yoon YW, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc
Ther. 2016 Oct;34(5):371-82. doi: 10.1111/1755-5922.12213. PMID: 27506635; PMCID: PMC5108468.
5. Yang LP, Keating GM. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. Am J Cardiovasc Drugs. 2009;9(6):401-9.
6. Food and Drugs Administration. lnformation on Fenofibric Acid (marketed as Trilipix). FDA; 2015.